Yubo International Biotech Limited
Symbole: YBGJ
PNK
0.325
USDPrix du marché aujourd'hui
-175.4014
Ratio P/E
-1.8389
Ratio PEG
38.94M
Cap MRK
- 0.00%
Rendement DIV
Yubo International Biotech Limited (YBGJ) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0.4 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 0.3 | 0 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 0.8 | 1.1 | 1.9 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1.4 | 3.3 | 0.4 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0.1 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 1.6 | 3.5 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.5 | 0.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.4 | 0.8 | 0.3 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 1.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 2.9 | 4.7 | 1.3 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -3.7 | -2.5 | -0.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | 0.1 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2.9 | 2.1 | 2 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.6 | -0.1 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 0.8 | 2.7 | -1.1 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 1.2 | 0.5 | 0.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.1 | -0.2 | 0 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -0.2 | -0.1 | -0.1 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 1 | 0.6 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.8 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.1 | 0.6 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0.1 | 1.4 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.1 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -1.4 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 1.4 | 0 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0.1 | -1 | 0.1 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -1.6 | 0 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0.1 | 1.2 | 1.4 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.1 | 0.4 | 0.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0.1 | 0.8 | 1.2 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 1.3 | 2.4 | 2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1.3 | 2.8 | 2.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -1.2 | -1.5 | -0.7 |
Questions fréquemment posées
Quel est le total de Yubo International Biotech Limited (YBGJ) de l'actif total?
Yubo International Biotech Limited (YBGJ) Le total des actifs est 2348551.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.390.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est -0.002.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est -2.586.
Quel est le revenu total de l'entreprise?
Le revenu total est -2.620.
Qu'est-ce que Yubo International Biotech Limited (YBGJ) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -1204765.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 790499.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 1257875.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.